| Item type |
文献 / Documents(1) |
| 公開日 |
2021-09-29 |
| アクセス権 |
|
|
アクセス権 |
open access |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1096/fba.1018 |
|
|
言語 |
ja |
|
|
関連名称 |
10.1096/fba.1018 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
S-Nitrosated alpha-1-acid glycoprotein exhibits antibacterial activity against multidrug-resistant bacteria strains and synergistically enhances the effect of antibiotics |
|
言語 |
en |
| 著者 |
異島, 優
ワタナベ, カオリ
Chuang, Victor T. G.
タケダ, イヨ
クロダ, テルオ
オガワ, ワカノ
ワタナベ, ヒロシ
イワオ, ヤスノリ
石田, 竜弘
オタギリ, マサキ
マルヤマ, トオル
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Alpha-1-acid glycoprotein (AGP) is a major acute-phase protein. Biosynthesis of AGP increases markedly during inflammation and infection, similar to nitric oxide (NO) biosynthesis. AGP variant A (AGP) contains a reduced cysteine (Cys149). Previously, we reported that S-nitrosated AGP (SNO-AGP) synthesized by reaction with a NO donor, possessed very strong broad-spectrum antimicrobial activity (IC50 = 10−9-10−6 M). In this study, using a cecal ligation and puncture animal model, we confirmed that AGP can be endogenously S-nitrosated during infection. Furthermore, we examined the antibacterial property of SNO-AGP against multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa to investigate the involvement of SNO-AGP in the host defense system. Our results showed that SNO-AGP could inhibit multidrug efflux pump, AcrAB-TolC, a major contributor to bacterial multidrug resistance. In addition, SNO-AGP decreased biofilm formation and ATP level in bacteria, indicating that SNO-AGP can revert drug resistance. It was also noteworthy that SNO-AGP showed synergistic effects with the existing antibiotics (oxacillin, imipenem, norfloxacin, erythromycin, and tetracycline). In conclusion, SNO-AGP participated in the host defense system and has potential as a novel agent for single or combination antimicrobial therapy. |
|
言語 |
en |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
alpha‐1‐acid glycoprotein |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
antimicrobial effect |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
multidrug resistance |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
nitric oxide |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
S‐nitrosation |
| 書誌情報 |
en : FASEB BioAdvances
巻 1,
号 3,
p. 137-150,
発行日 2018-09-01
|
| 収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
25739832 |
| 出版者 |
|
|
出版者 |
Federation of American Societies for Experimental Biology |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Wiley |
|
言語 |
en |
| 権利情報 |
|
|
言語 |
en |
|
権利情報 |
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| EID |
|
|
識別子 |
345876 |
|
識別子タイプ |
URI |
| 言語 |
|
|
言語 |
eng |
fba_1_3_137.pdf (1.43 MB)
.png)
